Jade

“So, you've, you know, previously discussed the potential for substantially less frequent MRI monitoring. Really, the question is, like, how and when would you evaluate whether this was reduced schedules appropriate, particularly in the ApoE4 homozygote?”

“So I just, just first of all, I just had a little blip in my audio, but did I understand correctly that you plan to submit the tuberculosis for ERPD assessment later this year?”

“So going back to Amandas and Vyandas, regarding those SNBA submissions, do you have any thoughts on timing for converting Exondas to full approval? As you guys spoke about, as of next month, it will have been on market for a full decade, but it's been on accelerated approval that whole time.”

“So just on Elevitus, could you comment on the recent FDA adverse event reporting system listed fatality due to cardiac and breathing issues, which was reported three weeks ago?”

“So, you stated today that the majority of previous Elevitus cancellations were reordered, but can you provide the actual hard numbers on the infusion postponements versus the number of cancellations you've gotten?”